Extending adjuvant trastuzumab treatment time provided no additional benefit

Name: Extending adjuvant trastuzumab treatment time provided no additional benefit
Uploaded: 2012-12-12T12:52:00+00:00
Description: At a press confernce at SABCS 2012, Prof Piccart presents data that conculdes one year of adjuvant trastuzumab should remain the standard of care for patients with HER2-postive early-stage breast cancer, according to data from the phase III HERA trial, which compared the efficacy and safety of one year and two years of treatment.

SABCS 2012

Published: 12 Dec 2012

Rating:

Save

Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium

At a press confernce at SABCS 2012, Prof Piccart presents data that conculdes one year of adjuvant trastuzumab should remain the standard of care for patients with HER2-postive early-stage breast cancer, according to data from the phase III HERA trial, which compared the efficacy and safety of one year and two years of treatment.